The role of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer
Medullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease...
Gespeichert in:
Veröffentlicht in: | Hellenic journal of nuclear medicine 2020-09, Vol.23 (3), p.321 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | 321 |
container_title | Hellenic journal of nuclear medicine |
container_volume | 23 |
creator | Şahin, Onur Erdem Uslu-Beşli, Lebriz Asa, Sertaç Sağer, Sait Sönmezoğlu, Kerim |
description | Medullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.OBJECTIVEMedullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.The records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities.MATERIALS AND METHODSThe records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scan |
doi_str_mv | 10.1967/s002449912220 |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2473417687</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473417687</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_24734176873</originalsourceid><addsrcrecordid>eNqVjj1rwzAURTW0kPRjzP7GLmokRbHssSR2srWD9iDsZ6KiSK4kE_Lvq0L7A8odLlzOgUvIirNX3lRqnRgTUjYNF0KwO7LkqmF0K4VakIeUPhnbVqqql8TrM0IMDiGMUNUHQ_fv-q2khY9Wr3cajB-A1x3t9oe_yXrIRRuDc-FK5-nHnUy26HOCq81nuOAwO2firYC3GOwAvfE9xidyPxqX8Pm3H8lL1-rdkU4xfM2Y8uliU49F9RjmdBJSbSQvT9XmH-g3FHlN2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473417687</pqid></control><display><type>article</type><title>The role of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Şahin, Onur Erdem ; Uslu-Beşli, Lebriz ; Asa, Sertaç ; Sağer, Sait ; Sönmezoğlu, Kerim</creator><creatorcontrib>Şahin, Onur Erdem ; Uslu-Beşli, Lebriz ; Asa, Sertaç ; Sağer, Sait ; Sönmezoğlu, Kerim</creatorcontrib><description>Medullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.OBJECTIVEMedullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.The records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities.MATERIALS AND METHODSThe records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities.The overall sensitivity of 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT were 72.4% and 88.1%, respectively in detecting recurrent or metastatic disease. In the group of patients, who had both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT within 6 months interval (median: 1.14 months; range: 0.03 - 5.7 months), no significant difference was found in the overall sensitivity of both imaging modalities, however 68Ga-DOTATATE PET/CT was found to be more sensitive in detection of bone lesions compared to 18F-FDG PET/CT (P=0.005).RESULTSThe overall sensitivity of 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT were 72.4% and 88.1%, respectively in detecting recurrent or metastatic disease. In the group of patients, who had both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT within 6 months interval (median: 1.14 months; range: 0.03 - 5.7 months), no significant difference was found in the overall sensitivity of both imaging modalities, however 68Ga-DOTATATE PET/CT was found to be more sensitive in detection of bone lesions compared to 18F-FDG PET/CT (P=0.005).Both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT are efficient imaging modalities in detection of recurrent or metastatic disease in MTC patients. Gallium-68-DOTATATE PET/CT could be more beneficial in detection of bone metastases with respect to 18F-FDG PET/CT.CONCLUSIONBoth 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT are efficient imaging modalities in detection of recurrent or metastatic disease in MTC patients. Gallium-68-DOTATATE PET/CT could be more beneficial in detection of bone metastases with respect to 18F-FDG PET/CT.</description><identifier>ISSN: 1790-5427</identifier><identifier>DOI: 10.1967/s002449912220</identifier><language>eng</language><ispartof>Hellenic journal of nuclear medicine, 2020-09, Vol.23 (3), p.321</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids></links><search><creatorcontrib>Şahin, Onur Erdem</creatorcontrib><creatorcontrib>Uslu-Beşli, Lebriz</creatorcontrib><creatorcontrib>Asa, Sertaç</creatorcontrib><creatorcontrib>Sağer, Sait</creatorcontrib><creatorcontrib>Sönmezoğlu, Kerim</creatorcontrib><title>The role of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer</title><title>Hellenic journal of nuclear medicine</title><description>Medullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.OBJECTIVEMedullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.The records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities.MATERIALS AND METHODSThe records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities.The overall sensitivity of 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT were 72.4% and 88.1%, respectively in detecting recurrent or metastatic disease. In the group of patients, who had both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT within 6 months interval (median: 1.14 months; range: 0.03 - 5.7 months), no significant difference was found in the overall sensitivity of both imaging modalities, however 68Ga-DOTATATE PET/CT was found to be more sensitive in detection of bone lesions compared to 18F-FDG PET/CT (P=0.005).RESULTSThe overall sensitivity of 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT were 72.4% and 88.1%, respectively in detecting recurrent or metastatic disease. In the group of patients, who had both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT within 6 months interval (median: 1.14 months; range: 0.03 - 5.7 months), no significant difference was found in the overall sensitivity of both imaging modalities, however 68Ga-DOTATATE PET/CT was found to be more sensitive in detection of bone lesions compared to 18F-FDG PET/CT (P=0.005).Both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT are efficient imaging modalities in detection of recurrent or metastatic disease in MTC patients. Gallium-68-DOTATATE PET/CT could be more beneficial in detection of bone metastases with respect to 18F-FDG PET/CT.CONCLUSIONBoth 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT are efficient imaging modalities in detection of recurrent or metastatic disease in MTC patients. Gallium-68-DOTATATE PET/CT could be more beneficial in detection of bone metastases with respect to 18F-FDG PET/CT.</description><issn>1790-5427</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqVjj1rwzAURTW0kPRjzP7GLmokRbHssSR2srWD9iDsZ6KiSK4kE_Lvq0L7A8odLlzOgUvIirNX3lRqnRgTUjYNF0KwO7LkqmF0K4VakIeUPhnbVqqql8TrM0IMDiGMUNUHQ_fv-q2khY9Wr3cajB-A1x3t9oe_yXrIRRuDc-FK5-nHnUy26HOCq81nuOAwO2firYC3GOwAvfE9xidyPxqX8Pm3H8lL1-rdkU4xfM2Y8uliU49F9RjmdBJSbSQvT9XmH-g3FHlN2Q</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Şahin, Onur Erdem</creator><creator>Uslu-Beşli, Lebriz</creator><creator>Asa, Sertaç</creator><creator>Sağer, Sait</creator><creator>Sönmezoğlu, Kerim</creator><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>The role of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer</title><author>Şahin, Onur Erdem ; Uslu-Beşli, Lebriz ; Asa, Sertaç ; Sağer, Sait ; Sönmezoğlu, Kerim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_24734176873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Şahin, Onur Erdem</creatorcontrib><creatorcontrib>Uslu-Beşli, Lebriz</creatorcontrib><creatorcontrib>Asa, Sertaç</creatorcontrib><creatorcontrib>Sağer, Sait</creatorcontrib><creatorcontrib>Sönmezoğlu, Kerim</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Hellenic journal of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Şahin, Onur Erdem</au><au>Uslu-Beşli, Lebriz</au><au>Asa, Sertaç</au><au>Sağer, Sait</au><au>Sönmezoğlu, Kerim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer</atitle><jtitle>Hellenic journal of nuclear medicine</jtitle><date>2020-09-01</date><risdate>2020</risdate><volume>23</volume><issue>3</issue><spage>321</spage><pages>321-</pages><issn>1790-5427</issn><abstract>Medullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.OBJECTIVEMedullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate (68Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers.The records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities.MATERIALS AND METHODSThe records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either 68Ga-DOTATATE PET/CT (n=61) and/or 18F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and 18F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities.The overall sensitivity of 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT were 72.4% and 88.1%, respectively in detecting recurrent or metastatic disease. In the group of patients, who had both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT within 6 months interval (median: 1.14 months; range: 0.03 - 5.7 months), no significant difference was found in the overall sensitivity of both imaging modalities, however 68Ga-DOTATATE PET/CT was found to be more sensitive in detection of bone lesions compared to 18F-FDG PET/CT (P=0.005).RESULTSThe overall sensitivity of 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT were 72.4% and 88.1%, respectively in detecting recurrent or metastatic disease. In the group of patients, who had both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT within 6 months interval (median: 1.14 months; range: 0.03 - 5.7 months), no significant difference was found in the overall sensitivity of both imaging modalities, however 68Ga-DOTATATE PET/CT was found to be more sensitive in detection of bone lesions compared to 18F-FDG PET/CT (P=0.005).Both 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT are efficient imaging modalities in detection of recurrent or metastatic disease in MTC patients. Gallium-68-DOTATATE PET/CT could be more beneficial in detection of bone metastases with respect to 18F-FDG PET/CT.CONCLUSIONBoth 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT are efficient imaging modalities in detection of recurrent or metastatic disease in MTC patients. Gallium-68-DOTATATE PET/CT could be more beneficial in detection of bone metastases with respect to 18F-FDG PET/CT.</abstract><doi>10.1967/s002449912220</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1790-5427 |
ispartof | Hellenic journal of nuclear medicine, 2020-09, Vol.23 (3), p.321 |
issn | 1790-5427 |
language | eng |
recordid | cdi_proquest_miscellaneous_2473417687 |
source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
title | The role of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-06T07%3A30%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%2068Ga-DOTATATE%20PET/CT%20and%2018F-FDG%20PET/CT%20in%20the%20follow-up%20of%20patients%20with%20medullary%20thyroid%20cancer&rft.jtitle=Hellenic%20journal%20of%20nuclear%20medicine&rft.au=%C5%9Eahin,%20Onur%20Erdem&rft.date=2020-09-01&rft.volume=23&rft.issue=3&rft.spage=321&rft.pages=321-&rft.issn=1790-5427&rft_id=info:doi/10.1967/s002449912220&rft_dat=%3Cproquest%3E2473417687%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473417687&rft_id=info:pmid/&rfr_iscdi=true |